Diffuse large B-cell lymphoma not otherwise specified [DS:H02434]
Comment
Antibody-drug conjugate
Treatment of hematological cancers
Target
CD19 [HSA:930] [KO:K06465]
Pathway
hsa04151
PI3K-Akt signaling pathway
hsa04640
Hematopoietic cell lineage
Brite
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Loncastuximab Tesirine
D11338 Loncastuximab tesirine (USAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD19
D11338 Loncastuximab tesirine (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11338
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11338